A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results

Ahmed Hassan Fahal; Sahar Mubarak Bakhiet; El Samani Wadaa Mohamed; Eiman Siddig Ahmed; Osama El Hadi Bakhiet; Abu Bakar Ahmed Yousif; Lamis Ahmed Fahal; Hadel Yassir Atta Alla; A. Razig Osman A. Razig; Emmanuel Edwar Siddig; Omnia Babekir Hassan; Sahar A. Rahman Abdulla; Amir Faroug Mohaemd; Nagwa Adam Jodda; Mustafa El Nour Bahar; Borna A. Nyaoke; Thaddaeus Egondi; Peelen Oyieko; Eduard E. Zijlstra; Nathalie Strub-Wourgaft

doi:10.1093/mmy/myac072.s4.5a

A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results

Ahmed Hassan Fahal, Sahar Mubarak Bakhiet, El Samani Wadaa Mohamed, Eiman Siddig Ahmed, Osama El Hadi Bakhiet, Abu Bakar Ahmed Yousif, Lamis Ahmed Fahal, Hadel Yassir Atta Alla, A. Razig Osman A. Razig, Emmanuel Edwar Siddig, Omnia Babekir Hassan, Sahar A. Rahman Abdulla, Amir Faroug Mohaemd, Nagwa Adam Jodda, Mustafa El Nour Bahar, Borna A. Nyaoke, Thaddaeus Egondi, Peelen Oyieko, Eduard E. Zijlstra, Nathalie Strub-Wourgaft

Research output: Contribution to journal › Meeting Abstract › Popular

2 Citations (Web of Science)

Original language	English
Article number	myac072S45a
Pages (from-to)	16-16
Number of pages	1
Journal	Medical Mycology
Volume	60
Issue number	SUPP 1
DOIs	https://doi.org/10.1093/mmy/myac072.s4.5a
Publication status	Published - 20 Sept 2022
Externally published	Yes

Access to Document

10.1093/mmy/myac072.s4.5a

Cite this

Fahal, A. H., Bakhiet, S. M., Mohamed, E. S. W., Ahmed, E. S., Bakhiet, O. E. H., Yousif, A. B. A., Fahal, L. A., Alla, H. Y. A., Razig, A. R. O. A., Siddig, E. E., Hassan, O. B., Abdulla, S. A. R., Mohaemd, A. F., Jodda, N. A., Bahar, M. E. N., Nyaoke, B. A., Egondi, T., Oyieko, P., Zijlstra, E. E., & Strub-Wourgaft, N. (2022). A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results. Medical Mycology, 60(SUPP 1), 16-16. Article myac072S45a. https://doi.org/10.1093/mmy/myac072.s4.5a

Fahal, Ahmed Hassan ; Bakhiet, Sahar Mubarak ; Mohamed, El Samani Wadaa et al. / A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results. In: Medical Mycology. 2022 ; Vol. 60, No. SUPP 1. pp. 16-16.

@article{6c75a08cc7ce495aa155198020615960,

title = "A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results",

author = "Fahal, {Ahmed Hassan} and Bakhiet, {Sahar Mubarak} and Mohamed, {El Samani Wadaa} and Ahmed, {Eiman Siddig} and Bakhiet, {Osama El Hadi} and Yousif, {Abu Bakar Ahmed} and Fahal, {Lamis Ahmed} and Alla, {Hadel Yassir Atta} and Razig, {A. Razig Osman A.} and Siddig, {Emmanuel Edwar} and Hassan, {Omnia Babekir} and Abdulla, {Sahar A. Rahman} and Mohaemd, {Amir Faroug} and Jodda, {Nagwa Adam} and Bahar, {Mustafa El Nour} and Nyaoke, {Borna A.} and Thaddaeus Egondi and Peelen Oyieko and Zijlstra, {Eduard E.} and Nathalie Strub-Wourgaft",

year = "2022",

month = sep,

day = "20",

doi = "10.1093/mmy/myac072.s4.5a",

language = "English",

volume = "60",

pages = "16--16",

journal = "Medical Mycology",

issn = "1369-3786",

publisher = "Oxford University Press",

number = "SUPP 1",

}

Fahal, AH, Bakhiet, SM, Mohamed, ESW, Ahmed, ES, Bakhiet, OEH, Yousif, ABA, Fahal, LA, Alla, HYA, Razig, AROA, Siddig, EE, Hassan, OB, Abdulla, SAR, Mohaemd, AF, Jodda, NA, Bahar, MEN, Nyaoke, BA, Egondi, T, Oyieko, P, Zijlstra, EE & Strub-Wourgaft, N 2022, 'A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results', Medical Mycology, vol. 60, no. SUPP 1, myac072S45a, pp. 16-16. https://doi.org/10.1093/mmy/myac072.s4.5a

A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results. / Fahal, Ahmed Hassan; Bakhiet, Sahar Mubarak; Mohamed, El Samani Wadaa et al.
In: Medical Mycology, Vol. 60, No. SUPP 1, myac072S45a, 20.09.2022, p. 16-16.

Research output: Contribution to journal › Meeting Abstract › Popular

TY - JOUR

T1 - A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results

AU - Fahal, Ahmed Hassan

AU - Bakhiet, Sahar Mubarak

AU - Mohamed, El Samani Wadaa

AU - Ahmed, Eiman Siddig

AU - Bakhiet, Osama El Hadi

AU - Yousif, Abu Bakar Ahmed

AU - Fahal, Lamis Ahmed

AU - Alla, Hadel Yassir Atta

AU - Razig, A. Razig Osman A.

AU - Siddig, Emmanuel Edwar

AU - Hassan, Omnia Babekir

AU - Abdulla, Sahar A. Rahman

AU - Mohaemd, Amir Faroug

AU - Jodda, Nagwa Adam

AU - Bahar, Mustafa El Nour

AU - Nyaoke, Borna A.

AU - Egondi, Thaddaeus

AU - Oyieko, Peelen

AU - Zijlstra, Eduard E.

AU - Strub-Wourgaft, Nathalie

PY - 2022/9/20

Y1 - 2022/9/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000868689700042&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1093/mmy/myac072.s4.5a

DO - 10.1093/mmy/myac072.s4.5a

M3 - Meeting Abstract

SN - 1369-3786

VL - 60

SP - 16

EP - 16

JO - Medical Mycology

JF - Medical Mycology

IS - SUPP 1

M1 - myac072S45a

ER -

Fahal AH, Bakhiet SM, Mohamed ESW, Ahmed ES, Bakhiet OEH, Yousif ABA et al. A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results. Medical Mycology. 2022 Sept 20;60(SUPP 1):16-16. myac072S45a. doi: 10.1093/mmy/myac072.s4.5a

A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-top line results

Access to Document

Other files and links

Cite this